UC is the new AD $SYRE $ABVX not to mention the TL1As. Super crowded. Real prize is Crohns.

Serious questions. Will $ERAS $BBOT $ANL etc be able to even recruit patients after this $RVMD data?

lol $anl like the name implies

Looks like the $anl drug having issues in china

Looks like today was shitco day $XBI Good short list brewing

$NKTR data is great but when dealing in such a small N drawing large conclusions regarding competitive landscape is premature 2 patients here or there could change the perspective. Now we wait for p3 results.

$NKTR proving that simplicity works best vs all the complicated and shitty IL2 therapies like $pand $howl $cue

Stephen Ayers has made a brilliant observation. $NKTR are using multiple imputation for the SALT20! This is sneaky and unacceptable for a binary outcome. Alarmingly there is no reason to do this; you simple count those hitting the SALT20 and assume everyone else is a non- responder.

Fully enough they did something similar with Bempeg

$NKTR pricing at 90/95?

$cue shitco gonna shitco

$cue opening at 15 is going to get shorted hard

How does $CUE not have a single therapeutic preclinical model? Everything is prophylactic. That’s a farse.

$NKTR people really thought that management could handpick data and take the stock significantly higher?

$anl should be up

$CPRX buyout makes zero sense when you realize they don’t even own the European rights to agamree…

Uffff $eras don’t chase china $anl

$cue someone tried to squeeze it up yesterday and failed so they are dumping their shares now. Thank you for the cheapies.

Ufff $NKTR down 20% from highs 😂

Imagine having sold puts on $nktr 😂